Endava Announces Third Quarter Fiscal Year 2026 Results
Q3 FY2026
8.4% Year on Year Revenue Decline to £178.5 million
6.4% Revenue Decline at Constant Currency
Diluted EPS £(7.55) compared to £0.18 in the prior year comparative period
Adjusted Diluted EPS £0.05 compared to £0.34 in the prior year comparative period
"This has been one of the more challenging periods
We are disappointed by these outcomes, but it is important to distinguish near-term execution challenges from our long-term strategic positioning. During the quarter, we accelerated our transition toward AI-native delivery and deepened our presence in payments transformation work. We also engaged more directly with senior client decision-makers on enterprise-scale AI initiatives.
We recently announced a collaboration with Mastercard combining our AI-native engineering and industry expertise with Mastercard’s global reach and data-driven products and services. Additionally, we were selected as a strategic partner by Tyl by NatWest, NatWest Group’s merchant-payments arm, to modernize and expand its payments-acceptance platform.
These initiatives, and others like them, have moved our AI driven business up from 5% of total revenue a year ago in Q3FY25, to 15% of total revenue in Q3FY26, showing the underlying momentum of our pivot.
By keeping our teams focused on these priorities and serving as trusted partners to decision-makers who are redefining their technology roadmaps, we believe we are positioning
THIRD QUARTER FISCAL YEAR 2026 FINANCIAL METRICS:
- Revenue for Q3 FY2026 was £178.5 million, a decline of 8.4% compared to £194.8 million in the same period in the prior year.
- Revenue decline at constant currency (a non-IFRS measure)* was 6.4% for Q3 FY2026.
- Loss before tax for Q3 FY2026 was £(372.0) million, compared to profit before tax of £13.6 million in the same period in the prior year.
- Adjusted profit before tax (a non-IFRS measure)* for Q3 FY2026 was £3.2 million, or 1.8% of revenue, compared to £24.6 million, or 12.6% of revenue, in the same period in the prior year.
- Loss for the period was £(394.4) million, resulting in diluted loss per share of £(7.55), compared to profit for the period of £10.9 million and diluted earnings per share ("EPS") of £0.18 in the same period in the prior year.
- Adjusted profit for the period (a non-IFRS measure)* was £2.6 million, resulting in adjusted diluted EPS (a non-IFRS measure)* of £0.05, compared to adjusted profit for the period of £20.1 million and adjusted diluted EPS of £0.34 in the same period in the prior year.
- During the quarter, an impairment of £364.6 million was recognised against goodwill, which is included as an exceptional item in the condensed consolidated statements of comprehensive income. This goodwill impairment has arisen due to the performance of the Company in the year to date, as well as management's reforecast of the Company's future performance through to FY31 and into perpetuity, by comparing the Company's recoverable amount derived from future forecasts to the Company's enterprise value. No goodwill impairment was recognised in the same period in the prior year.
-
During the quarter the Group incurred a tax charge of £23.2m relating to the derecognition of the entire
UK deferred tax asset. The amount is included as an exceptional item in the condensed consolidated statements of comprehensive income. The derecognition follows a reassessment of the recoverability of the deferred tax asset based on updated expectations for futureUK taxable profits. The reassessment is consistent with the reforecast of the company’s future performance considered in the assessment of the recoverable value of goodwill.
CASH FLOW:
- Net cash used in operating activities was £(0.4) million in Q3 FY2026, compared to net cash from operating activities of £18.7 million in the same period in the prior year.
- Adjusted free cash flow (a non-IFRS measure)* was £(3.1) million in Q3 FY2026, compared to £17.5 million in the same period in the prior year.
-
At
March 31, 2026 ,Endava had cash and cash equivalents of £48.4 million, compared to £59.3 million atJune 30, 2025 .
* Definitions of the non-IFRS measures used by the Company and a reconciliation of such measures to the related IFRS financial measure can be found under the sections below titled “Non-IFRS Financial Information” and “Reconciliation of IFRS Financial Measures to Non-IFRS Financial Measures.”
OTHER METRICS FOR THE QUARTER ENDED
-
Headcount totaled 11,225 at
March 31, 2026 , with an average of 10,166 operational employees in Q3 FY2026, compared to a headcount of 11,365 atMarch 31, 2025 and an average of 10,272 operational employees in the same period in the prior year. -
Number of clients with over £1 million in revenue on a rolling twelve-month basis was 129 at
March 31, 2026 compared to 136 clients atMarch 31, 2025 . - Top 10 clients accounted for 40% of revenue in Q3 FY2026, compared to 39% in the same period in the prior year.
-
By geographic region, 38% of revenue was generated in
North America , 23% was generated inEurope , 33% was generated in theUnited Kingdom and 6% was generated in the rest of the world in Q3 FY2026. This compares to 37% inNorth America , 22% inEurope , 35% in theUnited Kingdom and 6% in the Rest of the World in the same period in the prior year. - By industry vertical, 23% of revenue was generated from Payments, 22% from BCM, 9% from Insurance, 16% from TMT, 8% from Mobility, 11% from Healthcare, and 11% from Other in Q3 FY2026. This compares to 19% from Payments, 21% from BCM, 9% from Insurance, 18% from TMT, 8% from Mobility, 12% from Healthcare, and 13% from Other in the same period in the prior year.
OUTLOOK:
Fourth Quarter Fiscal Year 2026:
Full Fiscal Year 2026:
This above guidance for the fourth quarter and full fiscal year 2026 assumes the exchange rates on
The guidance provided above is forward-looking in nature. Actual results may differ materially. See “Forward-Looking Statements” below.
SHARE REPURCHASE PROGRAM:
As of
CONFERENCE CALL DETAILS:
The Company will host a conference call at
Investors may listen to the call on Endava’s Investor Relations website at http://investors.Endava.com. The webcast will be recorded and available for replay until
ABOUT
Endava’s clients span payments, insurance, banking and capital markets, technology, media, telecommunications, healthcare, mobility, retail and consumer goods and more. As of
NON-IFRS FINANCIAL INFORMATION:
To supplement Endava’s Condensed Consolidated Statements of Comprehensive Income, Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows presented in accordance with IFRS, the Company uses non-IFRS measures of certain components of financial performance in this press release. These measures include revenue (decline)/growth rate at constant currency, adjusted profit before tax, adjusted profit for the period, adjusted diluted EPS and adjusted free cash flow.
Revenue (decline)/growth rate at constant currency is calculated by translating revenue from entities reporting in foreign currencies into British Pounds using the comparable foreign currency exchange rates from the prior period. For example, the average currency rates in effect for the fiscal quarter ended
Adjusted profit before tax ("Adjusted PBT") is defined as the Company’s (loss)/profit before tax adjusted to exclude the impact of share-based compensation expense, amortisation of acquired intangible assets, realised and unrealised foreign currency exchange losses/(gains), net, goodwill impairment charge, restructuring costs, exceptional people charges, and fair value movement of contingent consideration, all of which are non-cash items except for realised foreign currency exchange losses/(gains), net, restructuring costs and exceptional people charges. Our Adjusted PBT margin is our Adjusted PBT as a percentage of our total revenue.
Adjusted profit for the period is defined as Adjusted PBT less the adjusted tax charge for the period. The adjusted tax charge is the tax charge adjusted for the tax impact of the adjustments to PBT, the release of the deferred tax liability relating to Romanian withholding tax and the reduction of the
Adjusted diluted EPS is defined as Adjusted profit for the period, divided by weighted average number of shares outstanding - diluted.
Adjusted free cash flow is the Company’s net cash from / (used in) operating activities, plus grants received, less net purchases of non-current assets (tangible and intangible). Adjusted free cash flow is not intended to be a measure of residual cash available for management's discretionary use since it omits significant sources and uses of cash flow, including mandatory debt repayments and changes in working capital.
Management believes these measures help illustrate underlying trends in the Company's business and uses the measures to establish budgets and operational goals, communicated internally and externally, for managing the Company's business and evaluating its performance. Management also believes the presentation of its non-IFRS financial measures enhances an investor’s overall understanding of the Company’s historical financial performance. The presentation of the Company’s non-IFRS financial measures is not meant to be considered in isolation or as a substitute for the Company’s financial results prepared in accordance with IFRS, and its non-IFRS measures may be different from non-IFRS measures used by other companies. Investors should review the reconciliation of the Company’s non-IFRS financial measures to the comparable IFRS financial measures included below and not rely on any single financial measure to evaluate the Company’s business.
FORWARD-LOOKING STATEMENTS:
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by the use of terms and phrases such as “believe,” “expect,” "intends," "outlook," “may,” “will,” and other similar terms and phrases. Such forward-looking statements include, but are not limited to, statements regarding our long-term strategic positioning,
|
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME |
Nine Months Ended |
Three Months Ended |
||||||
|
2026 |
2025 |
2026 |
2025 |
|||||
|
£’000 |
£’000 |
£’000 |
£’000 |
|||||
|
REVENUE |
540,823 |
|
585,479 |
|
178,538 |
|
194,838 |
|
|
Cost of sales |
|
|
|
|
||||
|
Direct cost of sales |
(413,131 |
) |
(417,317 |
) |
(139,292 |
) |
(134,251 |
) |
|
Allocated cost of sales |
(19,218 |
) |
(20,896 |
) |
(6,038 |
) |
(6,998 |
) |
|
Total cost of sales |
(432,349 |
) |
(438,213 |
) |
(145,330 |
) |
(141,249 |
) |
|
GROSS PROFIT |
108,474 |
|
147,266 |
|
33,208 |
|
53,589 |
|
|
Selling, general and administrative expenses |
(120,349 |
) |
(124,449 |
) |
(39,218 |
) |
(37,135 |
) |
|
|
(364,624 |
) |
— |
|
(364,624 |
) |
— |
|
|
OPERATING (LOSS) / PROFIT |
(376,499 |
) |
22,817 |
|
(370,634 |
) |
16,454 |
|
|
Net finance expense |
(11,151 |
) |
(2,503 |
) |
(1,318 |
) |
(2,857 |
) |
|
(LOSS) / PROFIT FOR THE PERIOD BEFORE TAX |
(387,650 |
) |
20,314 |
|
(371,952 |
) |
13,597 |
|
|
Tax on profit / (loss) on ordinary activities |
(21,855 |
) |
(270 |
) |
(22,490 |
) |
(2,651 |
) |
|
(LOSS) / PROFIT FOR THE PERIOD |
(409,505 |
) |
20,044 |
|
(394,442 |
) |
10,946 |
|
|
OTHER COMPREHENSIVE INCOME |
|
|
|
|
||||
|
Items that may be reclassified subsequently to profit or loss: |
|
|
|
|
||||
|
Exchange differences on translating foreign operations and net investment hedge impact |
4,945 |
|
(21,554 |
) |
(929 |
) |
(7,741 |
) |
|
Total comprehensive (expense) / income for the year attributable to the equity holders of the Company |
(404,560 |
) |
(1,510 |
) |
(395,371 |
) |
3,205 |
|
|
|
|
|
|
|
||||
|
(LOSS) / EARNINGS PER SHARE: |
|
|
|
|
||||
|
Weighted average number of shares outstanding - Basic |
52,716,456 |
|
59,234,601 |
|
52,234,286 |
|
59,164,297 |
|
|
Weighted average number of shares outstanding - Diluted |
52,716,456 |
|
59,566,531 |
|
52,234,286 |
|
59,434,080 |
|
|
Basic (Loss) / EPS (£) |
(7.77 |
) |
0.34 |
|
(7.55 |
) |
0.19 |
|
|
Diluted (Loss) / EPS (£) |
(7.77 |
) |
0.34 |
|
(7.55 |
) |
0.18 |
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|
|
|||
|
£’000 |
£’000 |
£’000 |
||||
|
ASSETS - NON-CURRENT |
|
|
|
|||
|
|
113,007 |
|
473,296 |
|
490,955 |
|
|
Intangible assets |
102,794 |
|
100,890 |
|
110,471 |
|
|
Property, plant and equipment |
14,998 |
|
14,177 |
|
15,036 |
|
|
Lease right-of-use assets |
37,013 |
|
41,515 |
|
44,240 |
|
|
Deferred tax assets |
7,342 |
|
19,030 |
|
20,792 |
|
|
Financial assets and other receivables |
3,258 |
|
5,009 |
|
9,141 |
|
|
TOTAL |
278,412 |
|
653,917 |
|
690,635 |
|
|
ASSETS - CURRENT |
|
|
|
|||
|
Trade and other receivables |
210,822 |
|
209,523 |
|
193,131 |
|
|
Corporation tax receivable |
1,029 |
|
12,865 |
|
10,084 |
|
|
Financial assets |
199 |
|
121 |
|
119 |
|
|
Cash and cash equivalents |
48,376 |
|
59,345 |
|
68,277 |
|
|
TOTAL |
260,426 |
|
281,854 |
|
271,611 |
|
|
TOTAL ASSETS |
538,838 |
|
935,771 |
|
962,246 |
|
|
LIABILITIES - CURRENT |
|
|
|
|||
|
Lease liabilities |
13,735 |
|
13,661 |
|
13,922 |
|
|
Trade and other payables |
104,960 |
|
96,827 |
|
101,161 |
|
|
Corporation tax payable |
7,198 |
|
7,757 |
|
6,088 |
|
|
Contingent consideration |
192 |
|
100 |
|
80 |
|
|
Deferred consideration |
— |
|
3,376 |
|
3,349 |
|
|
TOTAL |
126,085 |
|
121,721 |
|
124,600 |
|
|
LIABILITIES - NON CURRENT |
|
|
|
|||
|
Borrowings |
195,776 |
|
180,943 |
|
136,456 |
|
|
Lease liabilities |
29,099 |
|
33,448 |
|
35,225 |
|
|
Deferred tax liabilities |
13,841 |
|
15,183 |
|
19,674 |
|
|
Tax liabilities related to Pillar II Income tax |
646 |
|
584 |
|
— |
|
|
Contingent consideration |
159 |
|
401 |
|
329 |
|
|
Other liabilities |
592 |
|
552 |
|
377 |
|
|
TOTAL |
240,113 |
|
231,111 |
|
192,061 |
|
|
EQUITY |
|
|
|
|||
|
Share capital |
1,044 |
|
1,123 |
|
1,189 |
|
|
Share premium |
21,280 |
|
21,280 |
|
21,280 |
|
|
Merger relief reserve |
63,440 |
|
63,440 |
|
63,440 |
|
|
Retained earnings |
142,210 |
|
575,428 |
|
619,216 |
|
|
Other reserves |
(55,329 |
) |
(60,369 |
) |
(41,613 |
) |
|
|
— |
|
(17,958 |
) |
(17,922 |
) |
|
Investment in own shares |
(5 |
) |
(5 |
) |
(5 |
) |
|
TOTAL |
172,640 |
|
582,939 |
|
645,585 |
|
|
TOTAL LIABILITIES AND EQUITY |
538,838 |
|
935,771 |
|
962,246 |
|
|
(1) Restated to include the effect of revisions arising from provisional to final acquisition accounting for GalaxE. |
||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
Nine Months Ended |
Three Months Ended |
||||||
|
2026 |
2025 |
2026 |
2025 |
|||||
|
£’000 |
£’000 |
£’000 |
£’000 |
|||||
|
OPERATING ACTIVITIES |
|
|
|
|
||||
|
(Loss) / Profit for the period |
(409,505 |
) |
20,044 |
|
(394,442 |
) |
10,946 |
|
|
Income tax charge |
21,855 |
|
270 |
|
22,490 |
|
2,651 |
|
|
Non-cash adjustments |
415,116 |
|
64,720 |
|
377,451 |
|
18,513 |
|
|
Tax received / (paid) |
2,251 |
|
(6,943 |
) |
(1,643 |
) |
(3,157 |
) |
|
Research & Development Credit received |
8,567 |
|
— |
|
4,696 |
|
— |
|
|
Net changes in working capital |
1,757 |
|
(23,010 |
) |
(8,921 |
) |
(10,294 |
) |
|
Net cash from / (used in) operating activities |
40,041 |
|
55,081 |
|
(369 |
) |
18,659 |
|
|
|
|
|
|
|
||||
|
INVESTING ACTIVITIES |
|
|
|
|
||||
|
Purchase of non-current assets (tangibles and intangibles) |
(14,010 |
) |
(2,932 |
) |
(2,883 |
) |
(1,361 |
) |
|
Proceeds from disposal of non-current assets |
114 |
|
255 |
|
51 |
|
219 |
|
|
Payment for acquisition of subsidiary, net of cash acquired |
(4,443 |
) |
(6,676 |
) |
(857 |
) |
(776 |
) |
|
Interest received |
1,493 |
|
978 |
|
244 |
|
258 |
|
|
Net cash used in investing activities |
(16,846 |
) |
(8,375 |
) |
(3,445 |
) |
(1,660 |
) |
|
|
|
|
|
|
||||
|
FINANCING ACTIVITIES |
|
|
|
|
||||
|
Proceeds from borrowings |
54,903 |
|
35,000 |
|
11,903 |
|
25,000 |
|
|
Repayment of borrowings |
(43,634 |
) |
(40,842 |
) |
(20,304 |
) |
(10,000 |
) |
|
Proceeds from sublease |
90 |
|
92 |
|
37 |
|
28 |
|
|
Repayment of lease liabilities |
(9,478 |
) |
(9,357 |
) |
(2,895 |
) |
(3,198 |
) |
|
Repayment of lease interest |
(1,259 |
) |
(1,447 |
) |
(404 |
) |
(458 |
) |
|
Grant received |
105 |
|
274 |
|
95 |
|
— |
|
|
Interest and debt financing costs paid |
(7,707 |
) |
(6,510 |
) |
(2,545 |
) |
(2,228 |
) |
|
Payment for repurchase of own shares |
(27,431 |
) |
(17,808 |
) |
(2,446 |
) |
(17,808 |
) |
|
Net cash (used in) financing activities |
(34,411 |
) |
(40,598 |
) |
(16,559 |
) |
(8,664 |
) |
|
Net change in cash and cash equivalents |
(11,216 |
) |
6,108 |
|
(20,373 |
) |
8,335 |
|
|
|
|
|
|
|
||||
|
Cash and cash equivalents at the beginning of the period |
59,345 |
|
62,358 |
|
68,484 |
|
60,065 |
|
|
Effects of exchange rate changes on cash and cash equivalents |
247 |
|
(189 |
) |
265 |
|
(123 |
) |
|
Cash and cash equivalents at the end of the period |
48,376 |
|
68,277 |
|
48,376 |
|
68,277 |
|
RECONCILIATION OF IFRS FINANCIAL MEASURES TO NON-IFRS FINANCIAL MEASURES
|
RECONCILIATION OF REVENUE (DECLINE) / GROWTH RATE AS REPORTED UNDER IFRS TO REVENUE (DECLINE) / GROWTH RATE AT CONSTANT CURRENCY: |
||||||||
|
|
Nine Months Ended |
Three Months Ended |
||||||
|
|
2026 |
2025 |
2026 |
2025 |
||||
|
REVENUE (DECLINE) / GROWTH RATE AS REPORTED UNDER IFRS |
(7.6 |
)% |
7.2 |
% |
(8.4 |
%) |
11.7 |
% |
|
Impact of Foreign exchange rate fluctuations |
1.3 |
% |
1.6 |
% |
2.0 |
% |
0.7 |
% |
|
REVENUE (DECLINE) / GROWTH RATE AT CONSTANT CURRENCY |
(6.3 |
)% |
8.8 |
% |
(6.4 |
%) |
12.4 |
% |
|
RECONCILIATION OF ADJUSTED PROFIT BEFORE TAX AND ADJUSTED PROFIT FOR THE PERIOD: |
||||||||
|
|
Nine Months Ended |
Three Months Ended |
||||||
|
|
2026 |
2025 |
2026 |
2025 |
||||
|
|
£’000 |
£’000 |
£’000 |
£’000 |
||||
|
|
|
|
|
|
||||
|
(LOSS) / PROFIT BEFORE TAX |
(387,650 |
) |
20,314 |
|
(371,952 |
) |
13,597 |
|
|
Adjustments: |
|
|
|
|
||||
|
Share-based compensation expense |
18,594 |
|
28,186 |
|
4,418 |
|
6,221 |
|
|
Amortisation of acquired intangible assets |
15,240 |
|
16,236 |
|
5,070 |
|
4,054 |
|
|
Foreign currency exchange losses / (gains), net |
3,772 |
|
1,446 |
|
(1,070 |
) |
4,866 |
|
|
|
364,624 |
|
— |
|
364,624 |
|
— |
|
|
Restructuring costs |
9,056 |
|
5,494 |
|
2,525 |
|
— |
|
|
Exceptional people charges |
668 |
|
— |
|
— |
|
— |
|
|
Fair value movement of contingent consideration |
(626 |
) |
(5,963 |
) |
(457 |
) |
(4,092 |
) |
|
Total adjustments |
411,328 |
|
45,399 |
|
375,110 |
|
11,049 |
|
|
ADJUSTED PROFIT BEFORE TAX |
23,678 |
|
65,713 |
|
3,158 |
|
24,646 |
|
|
|
|
|
|
|
||||
|
(LOSS) / PROFIT FOR THE PERIOD |
(409,505 |
) |
20,044 |
|
(394,442 |
) |
10,946 |
|
|
Adjustments: |
|
|
|
|
||||
|
Adjustments to (loss) / profit before tax |
411,328 |
|
45,399 |
|
375,110 |
|
11,049 |
|
|
|
23,225 |
|
— |
|
23,225 |
|
— |
|
|
Release of Romanian withholding tax |
— |
|
(3,800 |
) |
— |
|
— |
|
|
Tax impact of adjustments |
(5,916 |
) |
(8,539 |
) |
(1,274 |
) |
(1,857 |
) |
|
ADJUSTED PROFIT FOR THE PERIOD |
19,132 |
|
53,104 |
|
2,619 |
|
20,138 |
|
|
RECONCILIATION OF ADJUSTED DILUTED EARNINGS PER SHARE: |
||||||||
|
|
Nine Months Ended |
Three Months Ended |
||||||
|
|
2026 |
2025 |
2026 |
2025 |
||||
|
|
£’000 |
£’000 |
£’000 |
£’000 |
||||
|
|
|
|
|
|
||||
|
DILUTED (LOSS) / EARNINGS PER SHARE (£) |
(7.77 |
) |
0.34 |
|
(7.55 |
) |
0.18 |
|
|
Adjustments: |
|
|
|
|
||||
|
Share-based compensation expense |
0.35 |
|
0.47 |
|
0.08 |
|
0.10 |
|
|
Amortisation of acquired intangible assets |
0.29 |
|
0.27 |
|
0.10 |
|
0.07 |
|
|
Foreign currency exchange losses / (gains) net |
0.07 |
|
0.02 |
|
(0.02 |
) |
0.08 |
|
|
|
6.92 |
|
— |
|
6.98 |
|
— |
|
|
Restructuring costs |
0.17 |
|
0.09 |
|
0.05 |
|
— |
|
|
Exceptional people charges |
0.01 |
|
— |
|
— |
|
— |
|
|
Fair value movement of contingent consideration |
(0.01 |
) |
(0.09 |
) |
(0.01 |
) |
(0.06 |
) |
|
|
0.44 |
|
— |
|
0.44 |
|
— |
|
|
Release of Romanian withholding tax |
— |
|
(0.06 |
) |
— |
|
— |
|
|
Tax impact of adjustments |
(0.11 |
) |
(0.15 |
) |
(0.02 |
) |
(0.03 |
) |
|
Total adjustments |
8.13 |
|
0.55 |
|
7.60 |
|
0.16 |
|
|
ADJUSTED DILUTED EARNINGS PER SHARE (£) |
0.36 |
|
0.89 |
|
0.05 |
|
0.34 |
|
|
RECONCILIATION OF |
||||||||
|
|
Nine Months Ended |
Three Months Ended |
||||||
|
|
2026 |
2025 |
2026 |
2025 |
||||
|
|
£’000 |
£’000 |
£’000 |
£’000 |
||||
|
|
|
|
|
|
||||
|
|
40,041 |
|
55,081 |
|
(369 |
) |
18,659 |
|
|
Adjustments: |
|
|
|
|
||||
|
Grant received |
105 |
|
274 |
|
95 |
|
— |
|
|
Net purchases of non-current assets (tangibles and intangibles) |
(13,896 |
) |
(2,677 |
) |
(2,832 |
) |
(1,142 |
) |
|
ADJUSTED FREE CASH FLOW |
26,250 |
|
52,678 |
|
(3,106 |
) |
17,517 |
|
SUPPLEMENTARY INFORMATION
|
SHARE-BASED COMPENSATION EXPENSE |
Nine Months Ended |
Three Months Ended |
||
|
|
2026 |
2025 |
2026 |
2025 |
|
|
£’000 |
£’000 |
£’000 |
£’000 |
|
|
|
|
|
|
|
Direct cost of sales |
12,309 |
19,550 |
3,026 |
4,502 |
|
Selling, general and administrative expenses |
6,285 |
8,636 |
1,392 |
1,719 |
|
Total |
18,594 |
28,186 |
4,418 |
6,221 |
|
DEPRECIATION AND AMORTISATION |
Nine Months Ended |
Three Months Ended |
||
|
|
2026 |
2025 |
2026 |
2025 |
|
|
£’000 |
£’000 |
£’000 |
£’000 |
|
|
|
|
|
|
|
Direct cost of sales |
13,240 |
15,571 |
3,958 |
5,158 |
|
Selling, general and administrative expenses |
17,095 |
18,525 |
5,592 |
4,805 |
|
Total |
30,335 |
34,096 |
9,550 |
9,963 |
|
EMPLOYEES, TOP 10 CUSTOMERS AND REVENUE SPLIT |
Nine Months Ended |
Three Months Ended |
||||||
|
|
2026 |
2025 |
2026 |
2025 |
||||
|
|
|
|
|
|
||||
|
Closing number of total employees (including directors) |
11,225 |
|
11,365 |
|
11,225 |
|
11,365 |
|
|
Average operational employees |
10,275 |
|
10,452 |
|
10,166 |
|
10,272 |
|
|
|
|
|
|
|
||||
|
Top 10 customers % |
35 |
% |
36 |
% |
40 |
% |
39 |
% |
|
Number of clients with > £1m of revenue (rolling 12 months) |
129 |
|
136 |
|
129 |
|
136 |
|
|
|
|
|
|
|
||||
|
Geographic split of revenue % |
|
|
|
|
||||
|
|
40 |
% |
38 |
% |
38 |
% |
37 |
% |
|
|
23 |
% |
24 |
% |
23 |
% |
22 |
% |
|
|
31 |
% |
33 |
% |
33 |
% |
35 |
% |
|
Rest of World (RoW) |
6 |
% |
5 |
% |
6 |
% |
6 |
% |
|
|
|
|
|
|
||||
|
Industry vertical split of revenue % |
|
|
|
|
||||
|
Payments |
20 |
% |
19 |
% |
23 |
% |
19 |
% |
|
Banking and Capital Markets |
22 |
% |
19 |
% |
22 |
% |
21 |
% |
|
Insurance |
9 |
% |
9 |
% |
9 |
% |
9 |
% |
|
TMT |
16 |
% |
20 |
% |
16 |
% |
18 |
% |
|
Mobility |
8 |
% |
8 |
% |
8 |
% |
8 |
% |
|
Healthcare |
12 |
% |
12 |
% |
11 |
% |
12 |
% |
|
Other |
13 |
% |
13 |
% |
11 |
% |
13 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520825840/en/
INVESTOR CONTACT:
Investors@endava.com
Source: